She runs a 15-person company in Hanover, New Hampshire that wants to make ethanol cheaper than gasoline using a bacterium that prefers temperatures most things would not survive.
She inherited a 30-year research dream. She's trying to ship it.
Lee Lynd has spent decades at Dartmouth's edge of a single, stubborn idea - that one engineered microbe should be able to do what a biofuel plant currently spends three expensive steps doing. The idea has a name: consolidated bioprocessing. It has been a research-paper dream since before most clean energy startups existed.
In March 2024, Lynd stepped aside as CEO of the company he co-founded to chase that dream commercially. He kept the title that mattered to him - Chief Technology Officer - and handed the rest to Kristin Brief.
The hand-off is the story. Scientist-founders rarely give up the corner office, and when they do, the person on the other side has to be the right shape of stubborn. Brief has spent twenty years near early-stage clean energy ventures. She helped build Virex Health from co-founder up to a Sorrento Therapeutics acquisition. She did an eighteen-month tour as a Business Fellow at Breakthrough Energy, the climate accelerator Bill Gates seeded with a thesis that science alone never decarbonizes anything - markets do.
Terragia is the consequence of that thesis meeting Lynd's lab. Engineered thermophilic bacteria - microbes that thrive at hot temperatures - eat cellulosic biomass directly, no pretreatment, no enzyme cocktails, no second fermentation tank. Corn stalks in, ethanol out. The pitch is not a moral one. It is a cost one.
Brief, when she talks about why she said yes, sounds almost suspicious of the word "differentiated." She uses it anyway. "Terragia's technology, team, and path to commercialization are differentiated," she said when she took the job. Said by someone selling a research dream, that line means little. Said by someone who has spent two decades watching clean energy startups die between the bench and the boiler, it carries weight.
That she runs the company from a town of roughly 11,000 people, several hours from any major venture capital cluster, is not incidental. Hanover, New Hampshire is where the science lives. Brief moved the executive office to where the work is.
Cellulosic ethanol traditionally requires harsh chemical pretreatment, a bath of expensive enzymes to break sugars free, and a separate fermentation to convert those sugars to fuel. Terragia's wager is to let an engineered, heat-loving bacterium do all of it at once.
Crop residue - corn stover, switchgrass, the leftovers - arrives without pretreatment.
Engineered thermophilic bacteria break cellulose down and ferment the sugars in a single hot vessel.
Ethanol and co-products come out the other side, targeting cost parity with petroleum.
Hanover is not just where Terragia's lab is - it's the town she went to school in. The science she's commercializing lives at the same institution.
Eighteen months inside the climate accelerator founded by Bill Gates. Focus: turning hard climate technologies into ventures investors can actually back.
Built a medical diagnostics company to an acquisition by Sorrento Therapeutics. Demonstrated the unglamorous operator skills Terragia now needs.
"Terragia's technology, team, and path to commercialization are differentiated." — Kristin Brief, on taking the CEO role
The decarbonization of transportation has, for two decades, depended on subsidy. Brief's wager is that a single engineered microbe and a one-pot process can change the math underneath - making low-carbon liquid fuel cheap enough that the policy debate becomes irrelevant. If that works, biofuels stop being a moral product and start being a market one. That's the whole game.